| BIO |
Bio-Rad Laboratories, Inc. |
72%
|
. Royalty expense is primarily recorded in cost of sales, with a small portion recorded as research and development expense depending on the use of the technology under license. Some of these agreeme… |
| BIO |
Bio-Rad Laboratories, Inc. |
72%
|
Reciprocal relationship from BIO graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from BIO graph: Reciprocal relationship from QGEN graph: . Royalty expense is primarily record… |
| CDNA |
CareDx, Inc. |
72%
|
Reciprocal relationship from CDNA graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from CDNA graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from CDNA g… |
| IDXG |
Interpace Biosciences, Inc. |
72%
|
Reciprocal relationship from IDXG graph: entific Inc., Illumina, Inc., Qiagen N.V., and F. Hoffmann-La Roche AG. While we have developed alternate sourcing strategies for most of these materials and … |
| MANU |
Manchester |
72%
|
emissions, we invested in equipping our Hilden, Germany facility with an emergency power supply and renewable heating systems. Capital expenditures for property, plant and equipment totaled $167.2 mi… |
| MANU |
Manchester |
72%
|
Reciprocal relationship from MANU graph: Reciprocal relationship from QGEN graph: emissions, we invested in equipping our Hilden, Germany facility with an emergency power supply and renewable heating… |
| PACB |
Pacific Biosciences of California, Inc. |
72%
|
Reciprocal relationship from PACB graph: We manufacture sequencing instruments, SMRT Cells, and reagents. Our key manufacturing and service facility in Menlo Park, California has received ISO 13485 a… |
| SAPGF |
SAP SE |
72%
|
Reciprocal relationship from SAPGF graph: Reciprocal relationship from QGEN graph: lity issues, we use long-term supply contracts as needed. In 2025, markets are experiencing increased pressure due t… |
| SAPGF |
SAP SE |
72%
|
lity issues, we use long-term supply contracts as needed. In 2025, markets are experiencing increased pressure due to ongoing geopolitical tensions, especially within Asia. The Company’s strong mater… |
| STQN |
Strategic Acquisitions, Inc. |
72%
|
Reciprocal relationship from STQN graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from STQN graph: Reciprocal relationship from QGEN graph: expand operations or integrate acqu… |
| STQN |
Strategic Acquisitions, Inc. |
72%
|
expand operations or integrate acquisitions could negatively impact our business and financial performance. We have grown significantly in recent years, with total net sales increasing from $1.87 bil… |
| VCYT |
Veracyte, Inc. |
72%
|
Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our produc… |
| VRAX |
Virax Biolabs Group Limited |
72%
|
Reciprocal relationship from VRAX graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from VRAX g… |
| LLP-WELLINGTON-INVESTMENT-ADVISORS-HOLDINGS |
LLP-WELLINGTON-INVESTMENT-ADVISORS-HOLDINGS |
62%
|
. (2) The 20,678,987 shares attributed to BlackRock, Inc. are reported as of January 31, 2026. Of the 20,678,987 shares attributed to BlackRock Inc. , it has sole voting power over 19,575,569 and sol… |
| OPERATING-ENVIRONMENT-COMPANY |
OPERATING-ENVIRONMENT-COMPANY |
62%
|
ement Report Corporate Governance Financial Statements Appendices Page 5 Management Report 6 Business and Operating Environment 7 Strategy, Business Model and Value Chain 12 Operating Environment 25 … |
| PARSE-BIOSCIENCES-INC |
PARSE-BIOSCIENCES-INC |
62%
|
. This growth has been driven by both organic expansion and strategic acquisitions, including the 2025 acquisitions of Parse Biosciences, Inc. and Genoox. We might continue acquiring businesses that … |
| QIAGEN-SCIENCES-LLC |
QIAGEN-SCIENCES-LLC |
62%
|
res for property, plant and equipment totaled $201.0 million in 2025 , $167.2 million in 2024 and $149.7 million in 2023 . These capital expenditures were financed from operating cash flows, and we e… |
| WELLINGTON-INVESTMENT-ADVISORS-HOLDINGS |
WELLINGTON-INVESTMENT-ADVISORS-HOLDINGS |
62%
|
. (2) The 20,678,987 shares attributed to BlackRock, Inc. are reported as of January 31, 2026. Of the 20,678,987 shares attributed to BlackRock Inc. , it has sole voting power over 19,575,569 and sol… |
| WELLINGTON-MANAGEMENT-COMPANY |
WELLINGTON-MANAGEMENT-COMPANY |
62%
|
. (2) The 20,678,987 shares attributed to BlackRock, Inc. are reported as of January 31, 2026. Of the 20,678,987 shares attributed to BlackRock Inc. , it has sole voting power over 19,575,569 and sol… |
| WELLINGTON-MANAGEMENT-GROUP |
WELLINGTON-MANAGEMENT-GROUP |
62%
|
. (2) The 20,678,987 shares attributed to BlackRock, Inc. are reported as of January 31, 2026. Of the 20,678,987 shares attributed to BlackRock Inc. , it has sole voting power over 19,575,569 and sol… |
| WELLINGTON-MANAGEMENT-GROUP-LLP-WELLINGTON-GROUP |
WELLINGTON-MANAGEMENT-GROUP-LLP-WELLINGTON-GROUP |
62%
|
. (2) The 20,678,987 shares attributed to BlackRock, Inc. are reported as of January 31, 2026. Of the 20,678,987 shares attributed to BlackRock Inc. , it has sole voting power over 19,575,569 and sol… |
